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Results: Preeclampsia!and!other!placenta!related!pregnancy!complications!increase the 













5.1.1 Preeclampsia!The!current!definition!of!preeclampsia!is!well!debated,!as!it!defines!a!syndrome!with!heterogeneous!pathophysiology!and!clinical!outcome,!but!there!is!general!consensus!to!include!the!criteria!of!new!onset!of!hypertension!and!proteinuria!in!the!second!half!of!the!pregnancy!(7).!Preeclampsia!is!a!syndrome!including!several!features,!both!maternal!and!fetal.!The pathogenesis is still unclear, but some characteristic components such as 
increased oxidative stress, genetic variance and placental and immunologic factors 
contribute on various pathophysiological levels in the process (9). Staff!et!al!recently!called!for!a!renewal!of!the!definition,!which!has!been!unchanged!despite!new!evidence!and!a!greater!understanding!of!the!disease!(10).!In!the!future,!preeclampsia!definition,!prevention!and!follow:up!may!also!involve!longitudinal!assessment!of!circulating!biomarkers!that!may!better!identify!subgroups!within!the!larger!and!more!heterogeneous!preeclampsia!group!(10).!!The!American!College!of!Obstetricians!and!Gynecologists!defines!preeclampsia!as!de!novo!hypertension!>140/90!mm!Hg!and!proteinuria!>0.3!g!per!24!hours!after!20!weeks!of!gestation!(11).!The!definition!is!now!under!revision!(10).!A!broader!approach!in!order!to!include!the!heterogeneity!of!preeclampsia!has!been!acknowledged!in!Australia!and!by!the!Society!of!Obstetricians!and!Gynecologists!of!Canada.!The!extended!definition!additionally!includes!(≥1)!new!fetal!or!maternal!features!such!as!fetal!growth!restriction!(FGR),!hepatocellular!dysfunction!or!renal!insufficiency!(12).!During!placentation,!mononuclear!extra!villous!fetal!cytotrophoblasts!invade!between!week!8!and!18!the!placental!bed!and!its!uteroplacental!spiral!arteries!(10).!The!invasion!occurs!either!interstitially!or!via!the!blood!vessels!into!the!decidual!lining!(which!is!the!endometrium!in!pregnancy)!and!the!inner!third!of!the!myometrium!(9).!The!spiral!arteries!are!in!normal!pregnancy!extensively!remodeled!in!the!segments!of!the!inner!myometrium!and!terminal!decidua.!The!remodeling!mainly!constitutes!of!loss!of!smooth!muscle!and!extensive!dilatation!and!reduces!the!velocity,!pressure!and!pulsatility!of!the!utero:placental!blood!flow!(10).!
!!!
8!
In!preeclampsia,!the!endovascular!trophoblast!invasion!into!the!spiral!arteries!is!restricted!to!the!peripheral!parts!of!the!decidua.!The!remodeling!is!incomplete!and!the!spiral!arteries!remain!more!constricted!and!thick:walled!than!in!a!normal!pregnancy!(10).!Retention!of!vasoactive!smooth!muscle!in!the!vessels!might!lead!to!intermittent!flow!and!subsequent!dysfunctional!villous!flow!and!placental!increased!oxidative!end!endoplasmic!reticulum!(ER)!stress!as!a!result!(13).!The!current!understanding!is!that!this!placental!stress!stimulates!release!of!trophoblast:derived!factors!into!the!maternal!circulation,!which!again!contributes!to!the!exaggerated!maternal!inflammatory!response!that!characterizes!preeclampsia!(14).!In!addition,!there!may!be!many!factors!provoking!or!contributing!to!dysfunctional placentation: genes (including paternal genes), 





























































!! !! !! !! !!







































































2) Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 
2009;33:130-7 
3) Ness RB, Hubel CA.Risk for coronary artery disease and morbid preeclampsia: a 
commentary. Ann Epidemiol. 2005 Oct;15(9):726-33. Review. 
4) Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of 
cardiovascular disease and cancer in later life: systematic review and meta-analysis. 
BMJ. 2007 Nov 10;335(7627):974 
5) Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive 
pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes 
mellitus in the mother. Hypertension. 2009 Jun;53(6):944-51.  
6) Smith GC, Pell JP, Walsh D.Pregnancy complications and maternal risk of ischaemic 
heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001 Jun 23;357 
(9273):2002-6. 
7) Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers 
after pre-eclampsia: population based cohort study. BMJ. 2001 Nov 24;323 
(7323):1213-7. 
8) Ness RB, Hubel CA. Risk for coronary artery disease and morbid preeclampsia: a 
commentary. Ann Epidemiol 2005; 15:726-733. 
9) Staff AC, Dechend R, Pijnenborg R. Learning from the placenta: acute atherosis and 
vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future 
cardiovascular health. Hypertension. 2010 Dec;56(6):1026-34.  
10) Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, 
Charnock-Jones DS, Redman CW. Redefining preeclampsia using placenta-derived 
biomarkers. Hypertension. 2013 May;61(5):932-42.  
11) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. 
Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J 
Gynaecol Obstet. 2002; 77:67-75 
12) von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hyperns 
Pregnancy. 2003;22:143-148. Management of hypertension in pregnancy: executive 




13) Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physio-  logical 
consequences of conversion of the maternal spiral arteries for utero-  placental blood 
flow during human pregnancy. Placenta. 2009;30:473–482. 
14) Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors and preeclampsia. Front Biosci. 
2007;12:2395–2402. 
15) Newstead J, von Dadelszen P, Magee LA.Preeclampsia and future cardiovascular risk. 
Expert Rev Cardiovasc Ther. 2007 Mar;5(2):283-94. Review. 
16) Staff AC, Dechend R, Redman CW.Review: Preeclampsia, acute atherosis of the spiral 
arteries and future cardiovascular disease: Two new hypotheses. Placenta. 2013 Mar;34 
Suppl:S73-8.  
17) Redman CW, SargentIL. Immunologyofpre-eclampsia. AmJReprodImmunol 
2010;63(6):534e43. 
18) NICE guidelines: National Institute for Health and Clinical Excellence. Hypertension in 
pregnancy the management of hypertensive disorders during pregnancy, vol. CG107. 
London: Royal College of Obstetricians and Gynaecologists; 2010. 
www.nice.org.uk/guidance/CG107/Guidance 
19) Klungsøyr K, Morken NH, Irgens L, Vollset SE and Skjærven R.. Secular trends in the 
‘epidemiology of pre-eclampsia throughout 40 years in Norway: prevalence, risk factors 
and perinatal survival. Paediatric and Perinatal Epidemiology, 2012, 26, 190–198 
20) Lewis, G (ed) 2007. The Confidential Enquiry into Maternal and Child Health (CEMACH). 
Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer - 2003-
2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United 
Kingdom. London: CEMACH. 
21) Wikström AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic 
heart disease after gestational hypertensive disease. BJOG. 2005 Nov;112 (11):1486-91. 
22) Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA.Cardiovascular health after maternal 
placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 
2005 Nov 19;366 (9499):1797-803.  
23) Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C, et al. The pre-eclampsia 
community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in 
the community. BMJ 2005;330:576-80. 
24) Magnussen EB, Vatten LJ, Myklestad K, Salvesen KÅ, Romundstad PR. Cardiovascular 
risk factors prior to conception and the length of pregnancy: population-based cohort 
study.Am J Obstet Gynecol. 2011 Jun;204(6):526.e1-8.  
!!!
29!
25) Catov JM, Newman AB, Roberts JM, et al. Preterm delivery and later maternal 
cardiovascular disease risk. Epidemiology 2007;18: 733-9. 
26) Goldenberg RL, Culhane JF, Iams JD, Ro- mero R. Epidemiology and causes of preterm 
birth. Lancet 2008;371:75-84. 
27) Castles A, Adams K, Melvin CL, Kelsch C, Boulton ML. Effects of smoking during 
pregnancy. Am J Prev Med 1999;16:208-15. 
28) Ness RB, Roberts JM. Heterogeneous causes constituting the single syn-  drome of 
preeclampsia: a hypothesis and its implications. Am J Obstet  Gynecol. 1996;175:1365–
1370. 
29) Clausen T, Slott M, Solvoll K, Drevon CA, Henriksen T. High intake of energy, sucrose 
and polyunsaturated fatty acids is associated with increased risk of preeclampsia. Am J 
Obstet Gynecol. 2001;185:451-/8. 
30) Clausen T, Øyen N, Henriksen T. Pregnancy complications by overweight and residential 
area. A prospective study of an urban Norwegian cohort. Acta Obstetricia et 
Gynecologica. 2006; 85: 526-533. 
31) Kvehaugen AS, Melien Ø, Lingaas OH, Laivuori H, Øian P, Andersgaard AB, Dechend R, 
Staff AC. Single Nucleotide Polymorphisms in G Protein Signaling Pathway Genes in 
Preeclampsia. Hypertension. 2013 Jan;61:655-661 
32) Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in 
pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol. 
2009 Nov;114(5):961-70.  
33) Sugulle M, Herse F, Hering L, Mockel M, Dechend R, Staff AC. Cardiovascular 
biomarker midregional proatrial natriuretic peptide during and after preeclamptic 
pregnancies. Hypertension. 2012 
34) Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC. Endothelial 
function and circulating biomarkers are disturbed in women and children after 
preeclampsia. Hypertension. 2011 Jul;58(1):63-9. 
35) Fugelseth D, Ramstad HB, Kvehaugen AS, Nestaas E, Støylen A, Staff AC. Myocardial 
function in offspring 5–8 years after pregnancy complicated by preeclampsia. Early 
Human Development. 2011 Apr;87:531–535 
36) Skjaerven R, Wilcox AJ, Klungsøyr K, Irgens LM, Vikse BE, Vatten LJ, Lie RT. 
Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, 
population based cohort study. BMJ. 2012 Nov 27;345:e7677.  
37) Kestenbaum B, Seliger SL, Easterling TR et al. Cardiovascular and thromboembolic 
events following hypertensive pregnancy. Am. J. Kidney Dis. 42(5), 982–989 (2003). 
!!!
30!
38) Wilson BJ, Watson MS, Prescott GJ et al. Hypertensive diseases of pregnancy and risk 
of hypertension and stroke in later life: results from cohort study. Br. Med. J. 326(7394), 
845 (2003). 
39) Männistö T, Mendola P, Vääräsmäki M, Järvelin MR, Hartikainen AL, Pouta A, E 
Suvanto. Elevated Blood Pressure in Pregnancy and Subsequent Chronic Disease Risk. 
Clinical Perspective  . Circulation 2013 July;127:681-690 
40) http://nhi.no/forside/skjema-og-kalkulatorer/kalkulatorer/norrisk-10-arsrisiko-for-
kardiovaskuler-dod-30384.html 
41) Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, 
Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J Kris Etherton 
PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, et 
al. Effectiveness-based guidelines for the prevention of cardiovascular disease in 
women--2011 update: a guideline from the American Heart Association.J Am Coll 
Cardiol. 2011 Mar 22;57(12):1404-23.  
42) Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais 
P, Varigos J, Lisheng L, Investigators IS. Effect of potentially modifiable risk factors 
associated with myocardial infarction in 52 countries (the INTERHEART study): case–
control study. Lancet. 2004; 364:937–52. 
43) Fra NGF kap 28 (not yet published) 
44) Young B, Hacker MR, Rana S. Physicians´ knowledge of future vascular disease in 
women with preeclampsia. Hypertens Pregnancy. 2012;31:50-8. 
45) Heidrich MB, Wenzel D, von Kaisenberg CS, Schippert C, von Versen-Höynck 
FM.Preeclampsia and long-term risk of cardiovascular disease: what do 
obstetrician-gynecologists know?BMC Pregnancy Childbirth. 2013 Mar 9;13:61.  
46) Stevens DU, Al-Nasiry S, Bulten J, Spaanderman ME. Decidual vasculopathy and 
adverse perinatal outcome in preeclamptic pregnancy. Placenta 2012; 33(8):630e3 !  
!!!
31!
9 Appendix!
9.1 Flow!chart!
!
